MediWound (MDWD) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Business strategy and achievements

• Focuses on non-surgical tissue repair with validated technology and 14 successful clinical trials.

• Holds FDA and EMA approvals for NexoBrid, targeting severe burns, and is developing EscharEx for chronic wounds.

• Owns a manufacturing facility to meet global demand and has attracted collaborations with major wound care companies.

• Maintains a strong cash position with over $50 million, supporting execution of strategic plans and profitability.

Commercialization and market expansion

• NexoBrid demand exceeds manufacturing capacity by threefold, with strong growth in the U.S. and Japan.

• U.S. market prioritized due to its potential, with 40 burn centers ordering and 76% revenue growth reported by Vericel.

• Pediatric indication recently approved in the U.S., Europe, and Japan, expected to impact revenue from 2026 onward.

• Europe and Japan also show high demand, but supply is limited to emergency cases until manufacturing expands.

Manufacturing and regulatory milestones

• New GMP facility construction completed; commissioning process underway, expected to take about a year.

• Commercial markets prioritized over government sales during supply constraints.

• Facility operationalization is a key catalyst for significant revenue growth in 2025 and 2026.